CARTITUDE-6 (EMagine) is a Phase 3 trial testing whether the BCMA-directed CAR-T therapy ciltacabtagene autoleucel (cilta-cel, Carvykti) can move into first-line treatment of transplant-eligible newly diagnosed multiple myeloma, compared with DVRd induction plus autologous stem-cell transplant and lenalidomide maintenance. Frontline cilta-cel is investigational and the primary readout is pending; Carvykti is currently FDA-approved only for relapsed/refractory myeloma. Sponsor: Janssen / Legend Biotech with the European Myeloma Network.
Discover KOL Sentiment on CARTITUDE-6 →Design — Phase 3 randomized (EMagine; MMY3005 / EMN28); ciltacabtagene autoleucel (Carvykti) vs DVRd induction + ASCT + lenalidomide maintenance, transplant-eligible newly diagnosed multiple myeloma, ~750 patients (NCT05257083). (trial design)
Primary endpoint — Progression-free survival — PENDING; no primary readout yet. (trial status)
Preliminary signal — High MRD-negativity in non-randomized cilta-cel cohorts (about 85.6% at 10^-6); not a randomized comparison. (early cohort data)
Overall survival — Secondary endpoint; no readout yet. (trial status)
Safety — CAR-T class effects (cytokine release syndrome, ICANS, delayed neurotoxicity) monitored per the CARVYKTI REMS; full frontline safety to be characterized at primary analysis. (trial design)
Regulatory / Sponsor — INVESTIGATIONAL frontline — not FDA approved; Carvykti is approved only in relapsed/refractory MM. Janssen / Legend Biotech with EMN. (FDA label)
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated July 21, 2026.
Top tweets by impressions — click to view on X
#mmsm #IMWG25
Summer of the CARTITUDE programs for Cilta Cel https://t.co/u3Wm2uAxPB
Newly diagnosed MM-
As we move toward classifying patients as quad eligible or not, the question is who still needs frontline ASCT?
Rather than stratifying by baseline risk, is MRD status after…
CARTITUDE-6 (EMagine) is the pivotal trial positioning cilta-cel as a potential front-line option in transplant-eligible NDMM. Direct competitor: MajesTEC-5 (teclistamab-based front-line). Results will determine whether CAR-T moves to first-line or remains reserved for relapsed disease.
Phase 3 randomized comparison of cilta-cel vs. standard of care (DVRd induction + ASCT + lenalidomide maintenance) in transplant-eligible NDMM. Preliminary cilta-cel arm signals include 85.6% MRD negativity at 10⁻⁶ in non-randomized cohorts. No primary endpoint readout yet.
Safety in front-line cohorts to be fully characterized at primary analysis. CAR-T class effects (CRS, ICANS, delayed neurotoxicity) remain monitored per established CARVYKTI REMS.
⚠️ Ongoing phase 3 — potential front-line CAR-T paradigm shift. CARTITUDE-6 (EMagine) is the pivotal trial positioning cilta-cel as a potential front-line option in transplant-eligible NDMM. Direct competitor: MajesTEC-5 (teclistamab-based front-line). Results will determine whether CAR-T moves to first-line or remains reserved for relapsed disease.
CARTITUDE-6, also called EMagine (MMY3005 / EMN28; NCT05257083), is a Phase 3, randomized trial evaluating the BCMA-directed CAR-T therapy ciltacabtagene autoleucel (cilta-cel, Carvykti) as first-line treatment of transplant-eligible newly diagnosed multiple myeloma, compared with daratumumab-VRd induction plus autologous stem-cell transplant and lenalidomide maintenance. It is run by Janssen / Legend Biotech with the European Myeloma Network.
No. CARTITUDE-6 has not yet reported its primary progression-free survival endpoint; the randomized readout is pending. Preliminary signals from non-randomized cilta-cel cohorts include high MRD-negativity (about 85.6% at the 10^-6 threshold), but these are not a randomized comparison against standard of care.
No. The first-line use of cilta-cel (Carvykti) in newly diagnosed transplant-eligible myeloma studied in CARTITUDE-6 is investigational and not FDA approved. Cilta-cel is approved only for relapsed or refractory multiple myeloma — after at least one prior line (expanded April 2024) and, originally, after four or more prior lines (accelerated approval February 2022).
CARTITUDE-6 is the pivotal trial testing whether a single BCMA CAR-T infusion could replace or reshape the standard induction-transplant-maintenance paradigm in newly diagnosed myeloma. A positive result could move CAR-T to the front line; it is often discussed alongside teclistamab-based frontline strategies such as MajesTEC trials as a defining question for the field.
As a CAR-T therapy, cilta-cel carries class-specific risks — cytokine release syndrome, immune effector cell-associated neurotoxicity (ICANS), and delayed neurotoxicity — all managed under the CARVYKTI REMS program. The full first-line safety profile will be characterized at the trial's primary analysis.